✦ LIBER ✦

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)

✍ Scribed by Pier Luigi Zinzani; Monica Tani; Alessandro Pulsoni; Marco Gobbi; Alessio Perotti; Stefano De Luca; Alberto Fabbri; Alfonso Zaccaria; Maria Teresa Voso; Pierpaolo Fattori; Luciano Guardigni; Sonia Ronconi; Maria Giuseppina Cabras; Luigi Rigacci; Amalia De Renzo; Enrica Marchi; Vittorio Stefoni; Mariapaola Fina; Cinzia Pellegrini; Gerardo Musuraca; Enrico Derenzini; Stefano Pileri; Stefano Fanti; Pier Paolo Piccaluga; Michele Baccarani

Book ID: 117784631
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 119 KB
Volume: 9
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(08)70039-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 trial of fludarabine and mitox

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

✍ Pier Luigi Zinzani; Monica Tani; Stefano Fanti; Vittorio Stefoni; Gerardo Musura 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 1 views

## Abstract ## BACKGROUND A prospective, single‐arm, open‐label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus radioimmunotherapy was conducted to evaluate efficacy and safety in patients with untreated, indolent, nonfollicular non‐Hodgkin lymphoma (NHL). ## METHO

Rituximab plus Short-Duration Chemothera

Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium

✍ Hainsworth, John D.; Spigel, David R.; Markus, Tiffanie M.; Shipley, Dianna; Tho 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 121 KB

A VM 26-based regimen for patients with

A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: A phase II trial of the eastern cooperative oncology group

✍ Leo I. Gordon; Janet Andersen; Stephanie Gregory; Joseph Mazza; Paul Chervenick; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 545 KB

Background. The epidophyllotoxin VM 26 has been shown to have single-agent activity in patients with diffuse aggressive lymphoma. In an attempt to determine its activity in combination with other agents known to be effective in lymphoma, a Phase I1 trial of a novel chemotherapy regimen was conducted